Skip to main content

Blade Therapeutics.

Setting up a biotech subsidiary of a US company in Australia needed Acclime’s guidance and support to fully benefit from R&D tax incentives.
  • Client industry:
    Life sciences
  • Services:
    R&D advisory, company registration, business compliance
  • Country:

Acclime is a great business partner to work with. They offer a one-stop service to cover everything required to manage an Australian subsidiary.

Having worked with Acclime in two R&D incentive applications, I highly recommend Acclime to other biotech companies who are considering setting up a subsidiary in Australia.

Acclime has been instrumental in guiding us successfully through the R&D Tax Incentive program to conduct clinical trials in Australia. Even though I had prior experience in applying this program, I have relied heavily reply on Acclime to keep our company compliant and up to date with local changes.

Shirley Chiang
VP Finance, Blade Therapeutics

About Blade Therapeutics

Blade Therapeutics is advancing innovative anti-fibrotic therapies to meet currently unserved patient needs. Several rare/orphan and chronic debilitating conditions manifest with fibrosis, a complex, pathologic process in which healthy cells are replaced by progressively worsening scar tissue (fibrosis). They are committed to developing disease modifying and lifesaving treatments.